Trump quietly signs FDA user fee reauthorization

With almost zero fanfare, President Donald Trump signed the FDA Reauthorization Act (FDARA) of 2017 into law on Aug. 18, approving the user fee agreements paid by pharmaceutical and medical device companies to the Food and Drug Administration (FDA).

While the legislation passed both houses with only one recorded no vote—coming from Sen. Bernie Sanders, I-Vermont—it didn’t match what Trump had proposed. His 2018 budget proposal called for doubling FDA user fees to $2 billion, even after several years of increases since the fees were last negotiated in 2012. The law will require pharma companies to put up $8 billion total for these review, while making other changes which could speed up approvals. Those include requiring the FDA to set up an electronic submission system for 510(k) clearance and pre-market approval bids, modifying how the agency evaluates and approves applications and how they track device safety.

Supporters of the legislation in Congress said those changes match the spirit of the 21st Century Cures Act.

“Throughout the 21st Century Cures process, we heard about cutting-edge medical innovations that were on their way, but just out of reach,” House Energy and Commerce Committee Chairman Greg Walden, R-Oregon, said in a statement. “Ensuring these user fee programs are reauthorized will help connect the dots, bringing those innovations to light.”

The Medical Imaging and Technology Alliance (MITA) also praised the signing of FDARA. Among its favorite provisions were requirements for the FDA to produce, within 270 days of being signed into law, a report on device servicing quality and safety, which MITA said would address risks created when unregulated, third-party groups service devices improperly.

“We are confident that this legislation will be a critical component in ensuring that all patients have timely access to life-saving medical technologies,” said Joe Robinson, chairman of the MITA board of directors and senior vice president of health systems solutions at Philips Healthcare.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”